PLYMOUTH MEETING, PA — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is set to showcase its promising late-stage pipeline during an Investor Day event scheduled for October 1 in New York City. The event, beginning at 8:30 a.m. ET, will feature presentations from Harmony’s senior leadership and esteemed therapeutic area experts. The agenda highlights significant updates on key programs and their market potential.
Among the focal points of the presentation will be new data on pitolisant for treating idiopathic hypersomnia, along with progress in the pitolisant-HD development program. Additionally, Harmony will unveil fresh findings on BP1.15205, an emerging orexin-2 agonist that could become a leading treatment in its class. The company will also discuss the scientific rationale behind the therapeutic efficacy of ZYN002 and EPX100, both of which are advancing through Phase 3 trials.
A key topic will be the market opportunities for Harmony’s late-stage pipeline assets, especially following recent acquisitions that have expanded the company’s portfolio to include three orphan and rare central nervous system (CNS) franchises. Each franchise holds potential peak sales prospects ranging from $1 billion to $2 billion, underscoring Harmony’s strategic growth trajectory.
The Investor Day presentation will be accessible on the Harmony Biosciences website following the event. Interested investors are encouraged to register online for either in-person or virtual participation as attendance capacity is limited.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.